Skip to content

A Prospective Randomized Study Comparing the Effectiveness of Intra-articular Ketorolac Injection and Steroid Injection in Adhesive Capsulitis

A Prospective Randomized Study Comparing the Effectiveness of Intra-articular Ketorolac Injection and Steroid Injection in Adhesive Capsulitis

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200501002
Enrollment
84
Registered
2020-05-01
Start date
2020-04-28
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who have shoulder pain and diagnosed as having an adhesive capusiltis by the shoulder surgeons. Adhesive capsulitis&#44

Interventions

Experimental Drug,Active Comparator Drug
Ketorolac,Steroid
articular Ketorolac injection (30 mg) by an ultrasound guided injection ,Kenacot injection (30 mg) by an ultrasound guided injection

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
20 Years to 99 Years

Inclusion criteria

Inclusion criteria: &#45; Age > 20 years &#45; Painful shoulder within 6 months &#45; No improvement after the previous visit &#45; Limit ROM of affected shoulder &#45; Less than normal side >30° at least 2 directions &#45; Active ROM =< passive ROM &#45; Stage I and II (Hannafin & Chiaia)

Exclusion criteria

Exclusion criteria: 1) A person who had major shoulder trauma (fracture&#44; dislocation) 2) A person who has radiographic findings of significant glenohumeral joint arthritis such as systematic rheumatic disease or OA 3) A person who was diagnosed with massive rotator cuff tear 4) A person who was diagnosed with neurologic disorders such as cervical radiculopathy or stroke 5) A person with chronic steroid use 6) A person who is allergic to kerorolac or steriods.

Design outcomes

Primary

MeasureTime frame
Pain score time zero&#44; 2&#44; 4&#44; 8&#44; 16&#44; 24&#45;weeks follow up periods VAS pain scale

Secondary

MeasureTime frame
Functional outcomes time zero&#44; 2&#44; 4&#44; 8&#44; 16&#44; 24&#45;weeks follow up periods Thai&#45;SPADI score ,Shoulder range of motion time zero&#44; 2&#44; 4&#44; 8&#44; 16&#44; 24&#45;weeks follow up periods goniometer

Countries

Thailand

Contacts

Public ContactPhob Ganokroj

Faculty of Medicine Siriraj Hospital&#44; Mahidol University

phob.gan@mahidol.ac.th+66 945359522

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026